Biomarin Pharmaceutical (BMRN) Inventory Average (2010 - 2026)

Biomarin Pharmaceutical has disclosed Inventory Average across 17 years of filings, most recently posting $1.3 billion for Q1 2026.

• Quarterly Inventory Average rose 2.58% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 2.58% YoY) and the FY2025 annual result came in at $1.3 billion, up 8.19% from the prior year.
• Inventory Average slipped to $1.3 billion in Q1 2026, from $1.3 billion in the prior quarter.
• Over five years, Inventory Average peaked at $1.4 billion in Q3 2025 and troughed at $781.5 million in Q1 2022.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2024 — Inventory Average rose 23.84% — and 2026, when it gained 2.58%.
• Tracing BMRN's Inventory Average over 5 years: stood at $866.8 million in 2022, then grew by 23.41% to $1.1 billion in 2023, then rose by 12.74% to $1.2 billion in 2024, then advanced by 11.16% to $1.3 billion in 2025, then decreased by 4.06% to $1.3 billion in 2026.
• Business Quant data shows BMRN's Inventory Average at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.4 billion in Q3 2025.